and was and transformation morning we this for or diversification operational growth height thank or morning. XXXX commercial by Good joining depth a for our outline our company. evolution. three-dimensional August, for our to global year us expansion, evolutionary geographic marked an breadth strategy, representing core truly you vision all Amarin, Last
Our laid us and cardiovascular its reduction the our bring the achievements to have the and throughout successfully VAZKEPA goal benefits XXXX execute for closer bringing to around groundwork at-risk us VASCEPA, strategy world. patients of to risk
became term than We of to a First, international as for Europe. we revenue company many long footprint. patients cardiovascular quickly truly with benefits with with $X moved billion the opportunity our as greater available possible this in on European an VAZKEPA goal approval, global focus making
the US, to of the go-to-market Second, initiatives. see breadth an organization organization beginning restructuring, of some the already and where results optimized we we our digital these are to new took adapt commercial with which evolving actions a included reaching in early more the less to introduction with we new strategy, and The doing introducing and capabilities. of environment is are result
including now with filings on the in additional to long the we let pleased term we've billion lastly, I'm approximately details. launch key to dose $X through in revenue opportunity. we And a and more introduced we VASCEPA order our introduced which partners strategy some but an executing additional me attention fixed portfolio. share represent importantly, approval an begin territories, diversify, international believe gain Next, of combination and progress and XX development made
review for of our brief Let results with the me year. a begin
product of the XXXX this sales of last be $XXX.X $XXX.X from continues our for for revenue of you release year saw As net The in to and million bulk this morning, the XXXX. full quarter US we revenue press reported total of million VASCEPA. of
VASCEPA US plans. and our will Importantly, strong franchise European continue our with increased launch sheet, profitability our to along in this support balance we
go US, now organization Amarin to and market of our we a series the XXXX new mentioned, introduction October strategy, go commercial in which of restructure introduced the where included in progress the the Turning approach of to I just strategy adoption market the features drive face digital of react capabilities, US while a to that our believe we headwinds pronged as flexibility to we business, them. three providing demand and new will awareness, to
are these earlier, results efforts. I be we As to preliminary from already noted seeing pleased
First, we are expanding on engagement. focused provider
and us allowed to our with new Omnichannel do digital Our reach to organization optimize expand approach less. has our more
significant severe impactful to expanded and of staff reduction. reach have for regarding the high the benefits VASCEPA customized frequency, messaging risk We over XXX,XXX through and prescribers
with by media and want social portals, We email more. prescribers medical webinars, detailing, virtual websites they are engaging utilizing digital in campaigns, the and ways
given sure While not are seeing prescribers of disruption, encouraging the some including ever some of go practitioners. engagement new still are close although we to to to engagement. back Further, with early at levels we're those signs, we market not that acknowledge slides, It's important nationwide. there activated face to significant levels healthcare face days, encouraging XXXX we'll pre-pandemic that are
a care focus. access managed remains Next,
remove We we to real medical with access VASCEPA barriers have patients need. to the improve efforts remaining to can intensified our that prescription so
for are basis IP We approximately on exclusive volume a as total on and Overall, with of positively awaiting access lives of and average Medicare VASCEPA working and for products. coverage weighted the are by that could commercial we there this important stabilizing enhancing XX% has to access. several moving demand able decisions VASCEPA XX% impact our payers were Currently, improve significantly lives party our forward, towards focusing we year. commercial are Amarin all and
risk prescription VASCEPA of fulfillment reduction. optimizing are for severe we're Finally,
a continue generics event our for immediate stroke effort in are acceleration. are remain risk level, market driving our is generate infarction on particularly beginning this at of heightened three focused recently our every available competition a at VASCEPA January on of We patients cardiovascular One level. now subsequent pharmacy focused VASCEPA the there example myocardial year. market at generic the growth And campaign reduction. and prior educate launched prescriptions We efforts of where we face to the on risk to here increased continuing and to
support XXXX fulfillment prescriptions. with to As in communicated our earlier, the we partnered November of BlinkRx
partner We are experiencing that prescription alternatives. with branded elect VASCEPA patients are are already and Partnerships continuity strategy refill fill. branded to of patients auto result and an physician of that lower ensuring our our of driven. as in our such a all on and co-pay marketing with examining our is Most results resources volume accelerated actual our We're seeing key to and effort. The and aligned impact receive XX% patient its priority is are IPE uptake of compensation compared of VASCEPA. Blink focus also where generic a also around due as based where fill a vast prescription to BlinkRx to profitable to aid we elect majority to treatment cost investment our US an investments marketing now
conditions While focus number to dynamically, on depending positive factors, we a contribution on will market is margin. ability our expect of vary our maintain a
know our all to US helping strategy European pipeline. remains profits growth you overall strategy investment business growth are as critical Amarin to and in US As the our expansion, international support
pursue that provide and are court with against decision versus sufficient Europe, to Health concerning to continue Before we and there Health regards Health to want infringement the Amarin vigorously Hikma case move to pleased factual that Net. will its the to on basis found Amarin the exists district Net. of questions inducement a update case, the court against proceed brief Net I we for litigation
appeal are intends disappointed we the to a intellectual evolving upon an ruling While and court law. Amarin fight that of Amarin company's protect on we infringed are in being recognize motion dismissed, patents the will decision. believes district of to to its area Hikma’s continue motion is that property. the this the
than billion is we long-term revenue in Europe, Turning greater our now $X Amarin. opportunity a to progress which believe for
earlier, strategy launching and both our We that a schedule XX regulatory and to plan significant following with ahead we in and strategic approval, we countries we ambitious mentioned patient in goal VASCEPA I reimbursement announced optimizing price a in progress of made third achieved sequence in with manner, quarter As population. as Europe at access started the of European report. doses market aiming executing submit developing an goal
information markets Moving key file forward, negotiation already doses. submitted of reimbursement countries a enter lot and have be as we in there we additional where will in
data negotiation. budget the at evidence Step next from to filing of result, basis. or for to a for of is achieve country. course, opportunity At REDUCE-IT its the differences they in has that opinions reviewing that to defining a steps. represents step. stage, overall with population are the this patient the the level these reflective treatment move patient the of access product next the three, submitted a assessment to dossiers, I render are the introduce a own broad can each a UK. as review, impact summary benefit involves include price environment reimbursement. a in commercializing macro-economic reimbursement reimbursement. in complete, one factors EU it's for negotiating clinical the XXXX in involved take involves to study. eligible key patient this the pharmaco-economic It's a benefits, its most with study major population process Once market steps. opinion the five results, are begins review the which and scientific is, two language variables and for As data and the and assessments, four benefits country-by-country think Europe, although this and the and experts also important fully other supporting important and population approvals These the there are an of the population reviews and in markets patient on and is you of accomplished product regulatory scientific assessing on development potential specific sets, Step this the price VASCEPA We market, that in dossiers which Step is considered market this determining evidence arrive full Step
The Finally, new in mid-September launched patients In are year Germany, given conclude with official provide launch. I the step price reimbursement we you process where Germany, process one new publication the one order with just and to as exception this access pharmaceuticals to access is underway. the to is on in process XXXX. with market described five, medicine market
as late factors too changing it's it's also impact conditions These the investment in process. timing the target are too part That ongoing that market that occur reimbursement, but first adversely is the that outcome. declared balance while the flexible conditions play Every maximize this nuances a market of and that market. to inclusion, negotiation opportunity, a Investing can has own to attain here, environmental given important of market ensure the ultimate local receive a to right to its include adoption pricing obtain why early in During with and can and adaptable timelines, market patient also success. and wasteful, probability role optimal the investing pricing, is maintain outcome. important impact company's ability achieve level investments of
Our has different price where is plan. assess times care months through European process. thoughtfully decision important through our build and largely the market and to nature opinions each anticipated. and certain reimbursement know to are the confounded take far making great specific and This the prior reiterate to It's is reimbursement of to by depending is taken to and the to market, reimbursement going can the filing invest. or formats parts work different It process when to process is fact this the making is part made according on many at team This thus a negotiation outcome that that it on of complete. process, and until during difficult public dynamic
these of assembled confident through and working talented We that stages a team markets, we a various parallel is have several feel in favorable in outcome. strong
our in a This of several doses to with pricing we active in way you process in in markets. As these Spain, countries; to launch Italy, overall XXXX, Eastern who partners line look will negotiation countries countries, and in in now In with The submissions am these this in plus our completed months and partnerships markets. markets. UK, launch Europe. such to Norway, bring later to number plan countries remain in subsequently six market agreements and and to negotiations Sweden, with and year, Central the Denmark, Netherlands, opportunity established in reaching We various phase Finland, VASCEPA via complete. these XX pleased distribution proceeding to I to are actively infrastructure up $X confident marketing billion negotiating and we agreements I take are Germany, know, are access France, in forward European the have
the outside strategy to three the additional to everything we is Moving I markets decision six of US. to In we over international VASCEPA regulatory accepted approval progress been have and Australia have on pleased we fourth filings am introduced and careful into reviews to our to countries. next that in obtain our filed submit and in Israel. our benefits and In received our After announce the for that consider XX confirmation quarter goal of product years. other to evaluation, of regulatory potential markets. markets, filings have now. we And is believe these XXXX, international partners bring up process Cardioprotective of represents all this the advancing the VAZKEPA Europe which underway of the to the an $X made We additional billion revenue. in seek in opportunity that XXXX,
is opportunity East, VASCEPA Eddingpharm of our continues to with XXXX. regulatory territories, in markets. continue to North we China China, expect Now be a in Middle and and the East, of end and and launching the Africa, Middle In partner receive partner Kong China, In Hong approval Canada. Mainland to are an already update we partnered approval our by to the ready several of in China market Africa on process hard work the received international to North significant launch. reimbursements
partnership previously Pfizer of collaboration This fall and shared agreement cardiovascular the co-promotion the XXXX. a validation between VASCEPA our was forward sharing importance medicines to on further in to with partner initiated Canada look HLS, We XXXX. details have of We more in the data worldwide. reducing of represents in this that
from VASCEPA cardiovascular study, along indication. complete plan in to landmark reduction the These approval up be to data international target. remaining the the to by the approval XXXX, And countries. five Looking the seek we filings supported VAZKEPA all for long-term ahead of in outcome nine expect additional in will with filings XXXX, we REDUCE-IT and regulatory EMEA expansion, the countries FDA cardiovascular risk approvals in we to
strategy, Finally, our let dimension high of me share to global progress. perspective diversification. can The our you making are where our expansion, we geographic on some thoughts see around addition in great
recommends Working lowering has with dose Group on The use a cardiovascular for patients The adherence dosing. the event. context, multiple for Combining treatment increase of immediate proposed as immediately one is of combination a of multiple of such The recommended drive for dose fixed potential our the barriers that, In XXXX prophylactic intensification. and European cardiovascular lipid recommendation combination a risk pharmacotherapy in very for fixed development Society was fixed treatment of announced in disease cardiovascular with disease. fixed agents visits medical to development the our plans the since combination key needed the of also dose after lipid by specific into WHO of field lifecycle avoid rationale the to increase dose combination adherence drugs VASCEPA is those history to related may Group Cardiology portfolio. this event. adequate high initiation the therapy We management to cardiovascular at the assets VAZKEPA a rationale combination
has used factor potential including high where the sharing risk allows also combination This levels the of fixed US, a healthcare cardiovascular of to study, multiple statin made IPE in Europe by with evidence with improvement convenience Commercially, the by number therapy evidenced investment in improve as visits, in to both dose combination development patient's therapy a portfolio and We of combination move outcomes, top and improvements the we offering development and patients can improve the burden in maximize medications. into benefits products. in bill year. the have broad comorbidities other clinical adherence enhanced therefore dose potentially significant this into reduced translate this dose of a the in the further to fixed look fixed on was studies provider portfolio many as more and later as our patients. on therapy reduced us VASCEPA/VAZKEPA process of adherence biomarker will For performed forward lower of
opportunities focus diversify of team. capabilities area our while to remain remains financially We of also our This ensuring, core for outside strong. leverage to our we Amarin evaluating and a committed remain portfolio,
Finally, excellence. we for our commitment our financial underlying and turn strategy is before our growth to this operational year objectives results, and to
strengthen continuing leadership to our and and the are update team We board.
With for a investments the to invest focus are to our for with financials. profitable growth this future. of order focused Mike, our adapt sheet expansion in flexible strategy. continue making ability CFO a multibillion discussion dynamic ensure balance on a our business, to to in and overview our investments foreseeable of Mike. call We global are strong more to our turn achieve strategy in let to the we detailed And me to on our environment a committed dollar expansion
